Belief BioMed (BBM), headquartered in China, is a global innovative biotechnology company integrating the development, manufacturing and clinical application of gene therapy products. It was announced on the page published on ClinicalTrials.gov with the ID NCT07058662 that the phase 1/2 trials of BBM-D101 gene therapy developed for Duchenne Muscular Dystrophy will be initiated.
Table of Contents
BBM-D101 Gene Therapy Phase 1/2 Clinical Trial
The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.
BBM-D101 is a gene addition therapy based on engineered AAV delivery therapeutic protein gene cassette into muscle for treating DMD. Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.
BBM-D101 Clinical Trial – NCT07058662
Study Start (Estimated): 2025-06-30
Primary Completion (Estimated): 2027-06-30
Study Completion (Estimated): 2031-06-30
Number of Participants (Estimated): 9 (Male)
Locations: China
Ages Eligible for Study: 4 Years to 9 Years (Child)
BBM-D101 Phase 1/2 Participation Criteria
People must fulfill the inclusion requirements in order to be eligible. If a person has another ailment or is undergoing treatment that could prevent them from receiving gene therapy, they might not be able to participate. The complete set of inclusion and exclusion criteria can be found by clicking on this study link – NCT07058662 –.
How Can I Contact with Belief BioMed?
Name: Hanyang Hu
Phone Number: +86-021-33588288
Email: [email protected]
